AngioDynamics Oncology Surgery Biz Helps Drive 13% Sales Growth
This article was originally published in The Gray Sheet
AngioDynamics' sales advanced 13% to $50.1 million in the firm's most recent fiscal quarter, aided by strong growth in its Oncology/Surgery business, the firm reported Oct. 6
You may also be interested in...
Incoming AngioDynamics CEO Jan Keltjens will draw on his 20-plus years of device industry leadership experience, including as former chief exec of CryoCath Technologies, to shepherd "the next level" of growth at the company
The companies think they can build out the indications for zuranalone and SAGE-324 faster and more broadly and commercialize the drugs more effectively as partners.
The guidance document allows manufacturers to promote their dry-heat systems for mask bioburden reduction if they meet certain standards.